A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy

Blood

Volumn 128, Issue 2, 2016, Pages 249-252

  Lin, Jianhong ^a   Zhang, Weihong ^a,b   Zhao, Jian Jun ^a   Kwart, Ariel H ^a   Yang, Chun ^a,c   Ma, Dongdong ^d   Ren, Xiubao ^b   Tai, Yu Tzu ^a   Anderson, Kenneth C ^a   Handin, Robert I ^d   Munshi, Nikhil C ^a,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c Department of Clinical Laboratory   (China)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MATRIGEL; RED FLUORESCENT PROTEIN; SYNDECAN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL FATE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; EMBRYO; EMBRYO DEVELOPMENT; FISH MODEL; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VIVO STUDY; LARVA; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; PLASMA CELL; PRECLINICAL STUDY; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; ZEBRA FISH; ANIMAL; CANCER TRANSPLANTATION; EXPERIMENTAL NEOPLASM; METABOLISM; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; HETEROGRAFTS; HUMANS; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ZEBRAFISH;

EID: 85019712676     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-03-704460     Document Type: Article

References (13)

1. Amin SB, Yip WK, Minvielle S, et al. Gene expression profile alone is inadequate in predicting complete response in multiple myeloma. Leukemia. 2014;28(11):2229-2234.
2. Carrasco DR, Sukhdeo K, Protopopova M, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell. 2007;11(4):349-360.
3. Chesi M, Robbiani DF, Sebag M, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell. 2008;13(2):167-180.
4. Groen RW, Noort WA, Raymakers RA, et al. Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood. 2012;120(3):e9-e16.
5. Rongvaux A, Willinger T, Martinek J, et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol. 2014;32(4):364-372.
6. Tai YT, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128-3138.
7. Tai YT, Fulciniti M, Hideshima T, et al. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood. 2007;110(5):1656-1663.
8. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood. 2006;107(3):1092-1100.
9. Kim K, Kong SY, Fulciniti M, et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol. 2010;149(4):537-549.
10. Raje N, Kumar S, Hideshima T, et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood. 2004;104(13):4188-4193.
11. White RM, Sessa A, Burke C, et al. Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell. 2008;2(2):183-189.
12. Iwanami N. Zebrafish as a model for understanding the evolution of the vertebrate immune system and human primary immunodeficiency. Exp Hematol. 2014;42(8):697-706.
13. Lam SH, Chua HL, Gong Z, Lam TJ, Sin YM. Development and maturation of the immune system in zebrafish, Danio rerio: a gene expression profiling, in situ hybridization and immunological study. Dev Comp Immunol. 2004;28(1):9-28.